Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.38 |
| ▸ | GSK3A | P49840 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21900972 | 0.90 | GRM4 (0.37) | LRRK2GSK3AGSK3BGRM5NTRK1 | |
| SCHEMBL21900948 | 0.80 | CDC7 (0.41) | GRM5HTR2AHTR2CPIK3CA | |
| SCHEMBL29536029 | 0.80 | CDC7 (0.41) | GRM5HTR2AHTR2CPIK3CA | |
| SCHEMBL22688394 | 0.77 | PGK1 (0.37) | LRRK2 | |
| SCHEMBL26321523 | 0.74 | ALDH1A1 (0.38) | GSK3BMAPK1 | |
| SCHEMBL30176382 | 0.73 | GRM5 (0.35) | GRM5MAPK10MAPK8MAPK14MAPK1 | |
| SCHEMBL22688273 | 0.72 | LRRK2 (0.38) | LRRK2MAPK10MAPK8MAPK14MAP2K4 | |
| SCHEMBL21900955 | 0.72 | PDGFRB (0.36) | GRM5GRM4PIK3CA | |
| SCHEMBL21901248 | 0.71 | GRM5 (0.37) | GSK3AGSK3BGRM5MAPK1PIK3CA | |
| SCHEMBL21900949 | 0.71 | HDAC1 (0.34) | GRM5MAPK10MAPK8MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020247160-A1 | CONDENSED TRYCICLIC PYRROLES AS ALPHA-1 ANTITRYPSIN MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED. | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINC1, SERPINA3 | LRRK2 3780/4885GSK3A 315/4885GSK3B 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.